Current Research Studies

Cancer – AALL1931: An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived Asparaginases

Condition or Therapy:

Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma


Cancer and Blood Disorders
Study Number: AALL1931

What is the goal of this study?

The aim of this study is to learn more about the pharmacology of the drug RC-P, including its side effects.

Who can join the study?

This study may be a good fit for children and young adults who:

  • Have been diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Kasey Leger
Research Center: Center for Clinical and Translational Research